Melanoma News and Research

Latest Melanoma News and Research

Study finds additional targets for new therapies to treat advanced prostate cancer patients

In its early stages, prostate cancer requires androgens (hormones that promote the development and maintenance of male sex characteristics) for growth, and current first-line therapies target the receptor for these hormones to slow cancer's development and spread.

7 Jul 2010

Rogue stem cells capable of kick-starting melanoma skin cancer development discovered

Researchers at Stanford University School of Medicine in the US have discovered that rogue stem cells appear to be capable of kick-starting the development of melanoma skin cancer in humans.

3 Jul 2010

Small business says 10 percent tanning tax that starts today is overcooked

As of July 1, tanning salons have to charge customers a 10 percent tax on their services to help pay for part of the new health reform law and that requirement has attracted the howls of small business, NPR reports. "Tanning salon owners are outraged. They say the new tax is the last thing they need in a struggling economy.

2 Jul 2010

DNA damage caused by UVA radiation leads to melanoma

A new study by researchers at NYU School of Medicine found that UVA radiation damages the DNA in human melanocyte cells, causing mutations that can lead to melanoma. Melanocytes, which contain a substance called melanin that darkens the skin to protect it from the ultraviolet rays of the sun, are more vulnerable to UVA radiation than normal skin cells because they are unable to repair themselves as efficiently.

2 Jul 2010

Celgene signs definitive merger agreement to acquire Abraxis BioScience

Celgene Corporation and Abraxis BioScience Inc. today jointly announced the signing of a definitive merger agreement in which Celgene has agreed to acquire Abraxis BioScience. Under the terms of the merger agreement, each share of Abraxis BioScience common stock will be converted into the right to receive an upfront payment of $58.00 in cash and 0.2617 shares of Celgene common stock.

30 Jun 2010

Federal agencies, state governments take action to educate, protect against serious risks of indoor tanning

As the scientific evidence mounts, more federal agencies and state governments are taking action to educate and protect Americans against the serious risks of indoor tanning. Recent and pending legislation in numerous states restricting access to indoor tanning, along with the federal 10 percent indoor tanning tax that goes into effect on July 1, are important steps in keeping Americans safe from overexposure to ultraviolet (UV) radiation and the potential for future skin cancers.

30 Jun 2010

Scancell, immatics collaborate to develop ImmunoBody vaccines for colorectal cancer

Scancell Holdings Plc,, the developer of therapeutic cancer vaccines, today announces a research collaboration with immatics biotechnologies GmbH to explore the development of novel ImmunoBody® vaccines for colorectal cancer.

29 Jun 2010

BioAlliance Pharma presents abstracts on Loramyc, clonidine Lauriad at MASCC/ISOO 2010 symposium

BioAlliance Pharma SA, a company dedicated to the supportive care and treatment of cancer patients, has presented 2 abstracts on Loramyc® and clonidine Lauriad® at the MASCC/ISOO 2010 International Symposium (Vancouver, June 24-26, 2010). These two products belong to the supportive care pipeline of BioAlliance Pharma.

29 Jun 2010

Pain Therapeutics modifies strategic alliance with King Pharmaceuticals for REMOXY outside U.S.

Pain Therapeutics, Inc. announced today a modification of its strategic alliance with King Pharmaceuticals, Inc. for REMOXY outside the U.S. The move signals a desire to target Europe's small and growing market for strong pain medications.

28 Jun 2010

Cyclosporine treatment develops higher de novo cancer risk in liver transplant patients: Researchers

Researchers at Erasmus MC University Medical Centre in The Netherlands found that cyclosporine treatment is a significant risk factor for the development of de novo cancer in liver transplant patients. Full details appear in the July issue of Liver Transplantation, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

25 Jun 2010

Anti-inflammatory interventions may protect sensitive skin types from sunburn

As the beaches of Southern Europe prepare for this summer's influx of pale skinned British sun worshippers, new research from the University of Bradford has found that redheads are just as capable of making the melanin needed for a tan as the olive skinned locals.

25 Jun 2010

Oxsoralen-Ultra therapy for severe psoriasis now available in the U.S. on a limited supply basis

Valeant Pharmaceuticals International today announced that Oxsoralen-Ultra, its therapy for severe psoriasis, is now available again in the United States on a limited supply basis.

23 Jun 2010

Folic acid and vitamin B12 lower homocysteine levels in patients who experience heart attack: JAMA

Patients who had experienced a heart attack and lowered their blood homocysteine levels with folic acid and vitamin B12 supplementation did not have an associated lower risk of heart attack, coronary death or stroke, according to a study in the June 23/30 issue of JAMA. However, the researchers did find that folic acid supplementation did not increase the risk of cancer, which has been speculated.

23 Jun 2010

Michigan State University researchers analyze histiocytic sarcomas

Michigan State University veterinarians are taking part in a two-year, $5.3 million project to analyze five cancers in dogs, research that could offer new insight into canine cancer genes and their potential impact on the human form of the disease.

22 Jun 2010

Pfizer to discontinue commercial availability of Mylotarg for AML in U.S.

Pfizer Inc. announced today that based on discussions with the U.S. Food and Drug Administration (FDA), it will be discontinuing commercial availability of Mylotarg® (gemtuzumab ozogamicin for Injection) (used for the treatment of relapsed acute myeloid leukemia (AML)) in the United States and that it will be voluntarily withdrawing the new drug application (NDA) for Mylotarg effective October 15, 2010.

22 Jun 2010

OXiGENE reports encouraging data from ZYBRESTAT program at Glaucoma and Retinopathies 2010 conference

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that the company presented an update on its ZYBRESTAT ophthalmology program, including encouraging preclinical data showing that the company's topical formulation achieved target retina/choroid concentrations with minimal systemic exposure.

22 Jun 2010

Exelixis announces regaining of rights to develop and commercialize XL184

Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials.

21 Jun 2010

Prototype drug blocks MCL-1 protein that helps tumors survive treatment: Scientists

Scientists at Dana-Farber Cancer Institute have found a way to disable a common protein that often thwarts chemotherapy treatment of several major forms of cancer.

21 Jun 2010

Neupro improves wellbeing impaired by pain related to Restless Legs Syndrome

The first data to show that Neupro® (rotigotine transdermal system) significantly improved wellbeing and daily activities that are often impaired by pain related to Restless Legs Syndrome (RLS) were presented this week at the 14th International Congress of Parkinson's Disease and Movement Disorders in Buenos Aires, Argentina.

18 Jun 2010

Protect Your Lungs, LUNGevity Foundation announce merger

To combat the nation's number one cancer killer, non-profit organizations Protect Your Lungs and LUNGevity Foundation today announced they will join forces in an effort to fund research and hope for a cure for lung cancer. Together, the new organization hopes to create the same successful improvements for lung cancer mortality rates as those experienced by breast, prostate, and colon cancer. The merged organization, committed to elevating lung cancer on the national agenda, will operate under the name LUNGevity Foundation with offices in Washington, D.C. and Chicago.

18 Jun 2010

Melanoma News and Research

Latest Melanoma News and Research

Study finds additional targets for new therapies to treat advanced prostate cancer patients

Rogue stem cells capable of kick-starting melanoma skin cancer development discovered

Small business says 10 percent tanning tax that starts today is overcooked

DNA damage caused by UVA radiation leads to melanoma

Celgene signs definitive merger agreement to acquire Abraxis BioScience

Federal agencies, state governments take action to educate, protect against serious risks of indoor tanning

Scancell, immatics collaborate to develop ImmunoBody vaccines for colorectal cancer

BioAlliance Pharma presents abstracts on Loramyc, clonidine Lauriad at MASCC/ISOO 2010 symposium

Pain Therapeutics modifies strategic alliance with King Pharmaceuticals for REMOXY outside U.S.

Cyclosporine treatment develops higher de novo cancer risk in liver transplant patients: Researchers

Anti-inflammatory interventions may protect sensitive skin types from sunburn

Oxsoralen-Ultra therapy for severe psoriasis now available in the U.S. on a limited supply basis

Folic acid and vitamin B12 lower homocysteine levels in patients who experience heart attack: JAMA

Michigan State University researchers analyze histiocytic sarcomas

Pfizer to discontinue commercial availability of Mylotarg for AML in U.S.

OXiGENE reports encouraging data from ZYBRESTAT program at Glaucoma and Retinopathies 2010 conference

Exelixis announces regaining of rights to develop and commercialize XL184

Prototype drug blocks MCL-1 protein that helps tumors survive treatment: Scientists

Neupro improves wellbeing impaired by pain related to Restless Legs Syndrome

Protect Your Lungs, LUNGevity Foundation announce merger

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Melanoma News and Research

Latest Melanoma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in